deltatrials
Completed PHASE3 INTERVENTIONAL 8-arm NCT03334396

A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD1)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Sponsor: Eli Lilly and Company

Conditions Atopic Dermatitis
Interventions Baricitinib Placebo
Updated 25 times since 2017 Last updated: Aug 7, 2020 Started: Nov 23, 2017 Primary completion: Dec 6, 2018 Completion: Aug 16, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atopic Dermatitis, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 25 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Nov 2019 · 6 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Dec 2025 · 2 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

25 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Oct 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 20 earlier versions

  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  2. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Feb 2020 — Sep 2020 [monthly]

    Completed PHASE3

  4. Nov 2019 — Feb 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. May 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  7. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  8. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  9. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  10. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  11. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  12. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  13. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  14. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  15. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  16. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  17. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  18. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  19. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE3

  20. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Incyte Corporation
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Ahmedabad, India , Bangalore, India , Berlin, Germany , Blankenfelde-Mahlow, Germany , Bonn, Germany , Bordeaux, France , Bramsche, Germany , Brest, France , Brno, Czechia and 67 more locations